DeepMed Research

Lorcaserin

Generic Name: Lorcaserin

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₄ClN

CAS Number: 616202-92-7

Unique Ingredient Identifier: 637E494O0Z

Background: Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride.

In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets, 20 mg) to voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug. This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer.

Indication: For the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.

Associated Conditions: Obesity

Clinical Trials

Combination Nicotine Patch / Lorcaserin for Smoking Cessation

Phase 2

Completed

Conditions: Nicotine Dependence

Interventions: Drug: lorcaserin
Drug: nicotine patch
Drug: placebo lorcaserin

First Posted Date: 2016-09-20

Last Posted Date: 2019-05-07

Lead Sponsor: Duke University

Target Recruit Count: 97

Registration Number: NCT02906644

Locations: 🇺🇸
Duke Center for Smoking Cessation, Durham, North Carolina, United States

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

Phase 4

Terminated

Conditions: Schizophrenia
Overweight
Schizoaffective Disorder

Interventions: Drug: Placebo
Drug: Lorcaserin
Drug: Metformin

First Posted Date: 2016-06-10

Last Posted Date: 2021-03-03

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 71

Registration Number: NCT02796144

Locations: 🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸
Carolina Behavioral Care, Hillsborough, North Carolina, United States
🇺🇸
New York State Psychiatric Institute (NYSPI), Columbia University, New York, New York, United States

and more 1 locations

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

Phase 1

Completed

Conditions: Cocaine Use Disorder

Interventions: Drug: Lorcaserin
Drug: Cocaine Intravenous (IV)
Drug: Placebo comparator

First Posted Date: 2015-09-02

Last Posted Date: 2020-05-12

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 29

Registration Number: NCT02537873

Locations: 🇺🇸
Virginia Commonwealth University, Institute for Drug and Alcohol Studies, Richmond, Virginia, United States

Evaluating Muscle Weakness Improvement With Lorcaserin in ICU

Phase 1

Terminated

Conditions: Muscle Weakness
Sepsis

Interventions: Drug: Lorcaserin
Drug: Placebo

First Posted Date: 2015-08-14

Last Posted Date: 2020-01-13

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 5

Registration Number: NCT02523690

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Addressing Post Cessation Weight Gain

Phase 2

Terminated

Conditions: Smoking Cessation
Obesity

Interventions: Drug: Varenicline
Drug: lorcaserin
Drug: Placebo

First Posted Date: 2015-04-09

Last Posted Date: 2021-06-10

Lead Sponsor: Mayo Clinic

Target Recruit Count: 84

Registration Number: NCT02412631

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Lorcaserin in Obesity: Identification of CNS Targets Using FMRI

Phase 4

Active, not recruiting

Conditions: Weight Loss
Obesity

Interventions: Drug: Lorcaserin HCl
Drug: Placebo

First Posted Date: 2015-03-27

Last Posted Date: 2025-03-21

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 40

Registration Number: NCT02400359

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Lorcaserin hydrochloride

First Posted Date: 2015-03-25

Last Posted Date: 2015-11-03

Lead Sponsor: Eisai Inc.

Target Recruit Count: 10

Registration Number: NCT02398669

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

Phase 1

Completed

Conditions: Cocaine Abuse

Interventions: Drug: Placebo
Drug: Lorcaserin
Drug: Cocaine Infusion

First Posted Date: 2015-03-19

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 20

Registration Number: NCT02393599

Locations: 🇺🇸
Vince Associates Clinical Research, Inc., Overland Park, Kansas, United States

Lorcaserin for Preventing Weight Gain Among Smokers

Phase 1

Completed

Conditions: Weight Gain
Tobacco Use Disorder

Interventions: Drug: Varenicline
Drug: Lorcaserin

First Posted Date: 2015-03-19

Last Posted Date: 2017-06-06

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT02393547

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

Not Applicable

Completed

Conditions: Obesity

Interventions: Drug: Lorcaserin
Drug: Placebo

First Posted Date: 2015-03-17

Last Posted Date: 2018-06-11

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 137

Registration Number: NCT02388568

Locations: 🇺🇸
University of Pennsylvania Center for Weight and Eating Disorders, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy